TABLE 1.

Summary of contezolid (MRX-I) and linezolid activity when tested against 1,211 Gram-positive clinical isolates

Organism/antimicrobial agent	No. of isolates (cumulative %) inhibited at MIC (mg/liter) of:					MIC (mg/liter)
	0.12	0.25	0.5	1	2	MIC50	MIC90
S. aureus (n = 606)
Contezolid	2 (0.3)	54 (9.2)	406 (76.2)	142 (99.7)	2 (100.0)	0.5	1
Linezolid	1 (0.2)	10 (1.8)	270 (46.4)	322 (99.5)	3 (100.0)	1	1
MSSA (n = 398)
Contezolid	2 (0.5)	21 (5.8)	260 (71.1)	113 (99.5)	2 (100.0)	0.5	1
Linezolid	1 (0.3)	4 (1.3)	152 (39.4)	238 (99.2)	3 (100.0)	1	1
MRSA (n = 208)
Contezolid		33 (15.9)	146 (86.1)	29 (100.0)		0.5	1
Linezolid		6 (2.9)	118 (59.6)	84 (100.0)		0.5	1
CoNS (n = 100)
Contezolid	12 (12.0)	53 (65.0)	32 (97.0)	3 (100.0)		0.25	0.5
Linezolid	4 (4.0)	39 (43.0)	44 (87.0)	13 (100.0)		0.5	1
E. faecalis (n = 52)
Contezolid		4 (7.7)	29 (63.5)	15 (92.3)	4 (100.0)	0.5	1
Linezolid		4 (7.7)	27 (59.6)	16 (90.4)	5 (100.0)	0.5	1
E. faecium (n = 51)
Contezolid		2 (3.9)	30 (62.7)	17 (96.1)	2 (100.0)	0.5	1
Linezolid		2 (3.9)	28 (58.8)	19 (96.1)	2 (100.0)	0.5	1
Vancomycin susceptible (n = 25)
Contezolid		1 (4.0)	12 (52.0)	10 (92.0)	2 (100.0)	0.5	1
Linezolid		1 (4.0)	11 (48.0)	11 (92.0)	2 (100.0)	1	1
Vancomycin resistant (n = 26)
Contezolid		1 (3.8)	18 (73.1)	7 (100.0)		0.5	1
Linezolid		1 (3.8)	17 (69.2)	8 (100.0)		0.5	1
S. pneumoniae (n = 201)
Contezolid		2 (1.0)	35 (18.4)	160 (98.0)	4 (100.0)	1	1
Linezolid		2 (1.0)	34 (17.9)	161 (98.0)	4 (100.0)	1	1
Beta-hemolytic streptococci (n = 102)
Contezolid			4 (3.9)	95 (97.1)	3 (100.0)	1	1
Linezolid			3 (2.9)	97 (98.0)	2 (100.0)	1	1
Viridans group streptococci (n = 99)
Contezolid	1 (1.0)	4 (5.1)	29 (34.3)	64 (99.0)	1 (100.0)	1	1
Linezolid		5 (5.1)	28 (33.3)	65 (99.0)	1 (100.0)	1	1